For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
7
views
0
references
 Top references
cited by
68
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      0
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: not found

      Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

      Author(s):
      Publication date:
      Journal: Stroke
      Publisher: Ovid Technologies (Wolters Kluwer Health)
      Keywords: stroke, Markov model, anticoagulation, atrial fibrillation, intracranial hemorrhage, cost-effectiveness

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin.

          Related collections

          Author and article information

          Journal
          PubMed ID:: 23549134
          DOI:: 10.1161/STROKEAHA.111.000402

          Keywords: stroke,Markov model,anticoagulation,atrial fibrillation,intracranial hemorrhage,cost-effectiveness
          Data availability:
          Keywords: stroke, Markov model, anticoagulation, atrial fibrillation, intracranial hemorrhage, cost-effectiveness

          Comments

          Comment on this article

          scite_